title: I222 Neuraminidase mutations further reduce oseltamivir susceptibility of Indonesian Clade 2.1 highly pathogenic Avian Influenza A(H5N1) viruses.
abstract: We have tested the susceptibility to neuraminidase inhibitors of 155 clade 2.1 H5N1 viruses from Indonesia, isolated between 2006-2008 as well as 12 clade 1 isolates from Thailand and Cambodia from 2004-2007 using a fluorometric MUNANA-based enzyme inhibition assay. The Thailand and Cambodian clade 1 isolates tested here were all susceptible to oseltamivir and zanamivir, and sequence comparison indicated that reduced oseltamivir susceptibility we observed previously with clade 1 Cambodian isolates correlated with an S246G neuraminidase mutation. Eight Indonesian viruses (5%), all bearing I222 neuraminidase mutations, were identified as mild to extreme outliers for oseltamivir based on statistical analysis by box plots. IC50s were from 50 to 500-fold higher than the reference clade 1 virus from Viet Nam, ranging from 43-75 nM for I222T/V mutants and from 268-349 nM for I222M mutants. All eight viruses were from different geographic locales; all I222M variants were from central Sumatra. None of the H5N1 isolates tested demonstrated reduced susceptibility to zanamivir (IC50s all <5 nM). All I222 mutants showed loss of slow binding specifically for oseltamivir in an IC50 kinetics assay. We identified four other Indonesian isolates with higher IC50s which also demonstrated loss of slow binding, including one virus with an I117V mutation. There was a minimal effect on the binding of zanamivir and peramivir for all isolates tested. As H5N1 remains a potential pandemic threat, the incidence of mutations conferring reduced oseltamivir susceptibility is concerning and emphasizes the need for greater surveillance of drug susceptibility.
authors.affiliation: Commonwealth Scientific and Industrial Research Organisation, Materials Science and Engineering, Parkville, Victoria, Australia. mck245@csiro.au
authors.forename: Jennifer L
authors.initials: JL
authors.lastname: McKimm-Breschkin
authors.forename: Susan
authors.initials: S
authors.lastname: Barrett
authors.lastname: Pudjiatmoko
authors.forename: Muhammad
authors.initials: M
authors.lastname: Azhar
authors.forename: Frank Y K
authors.initials: FY
authors.lastname: Wong
authors.forename: Paul
authors.initials: P
authors.lastname: Selleck
authors.forename: Peter G
authors.initials: PG
authors.lastname: Mohr
authors.forename: James
authors.initials: J
authors.lastname: McGrane
authors.forename: Mia
authors.initials: M
authors.lastname: Kim
mesh_terms: D000998:Antiviral Agents / Q000494:pharmacology*; D024882:Drug Resistance, Viral / Q000235:genetics; D006801:Humans; D053124:Influenza A Virus, H5N1 Subtype / Q000187:drug effects* / Q000201:enzymology / Q000235:genetics*; D009154:Mutation; D009439:Neuraminidase / Q000235:genetics*; D053139:Oseltamivir / Q000494:pharmacology*
chemical_list: D000998:Antiviral Agents; D053139:Oseltamivir; D009439:Neuraminidase